Maintenance therapy for advanced hepatitis C doesnt work, say boffinsDecember 4th, 2008 - 1:04 pm ICT by ANI
Washington, Dec 4 (ANI): Researchers from Saint Louis University have revealed that maintenance therapy involving low-dose peginterferon has been found ineffective in patients with advanced hepatitis C.
Instead, the study showed that low-dose peginterferon maintenance therapy led to health decline in patients with liver disease over the course of four years.
“This course of treatment had been adopted by a number of doctors in the U.S. and in other countries, though it had yet to be proven to work. That practice should be stopped based on the results of this trial. There is no rationale for using maintenance therapy,” said Adrian Di Bisceglie, M.D., professor of internal medicine, chief of hepatology and co-director of the Liver Center at Saint Louis University.
“The treatment is clearly ineffective,” he added.
For patients with chronic hepatitis C, the prognosis varies. About half fully recover after an initial course of peginterferon and ribavirin anti-viral therapy that may last from six months to a year.
The remaining patients, known as non-responders, may improve but the virus is not eliminated.
During the study, the researchers looked at 1050 patients at 10 different clinical sites.
They gave patients peginterferon for three and a half years, but in lower doses to try to suppress but not eliminate the virus, with the hope of slowing the dire consequences of liver disease.
Half of the patients were treated with a low dose of peginterferon and half were put into a control group for a total of four years.
The results showed that maintenance therapy did not stop liver disease from progressing.
In addition, researchers were startled by the rate of progression of liver disease. After four years, 30 percent of the patients in both the treatment and control groups had developed liver failure, liver cancer, or had died.
Among those with milder cirrhosis, 10 to 12 percent developed severe liver disease, also unexpected.
“Hepatitis patients in these circumstances got very ill over the course of four years, surprisingly so,” said Di Bisceglie.
“The lesson we learned is that once chronic hepatitis C gets to the stage of advanced fibrosis, patients can decline rapidly,” he added.
The study is published in the New England Journal of Medicine. (ANI)
- New hope for hepatitis C sufferers - Apr 09, 2010
- Coffee can cure hepatitis C - Jun 08, 2011
- Drug cocktail shows promise against hepatitis C - Mar 31, 2011
- Success of hepatitis C treatment may depend on genetic variant - Jun 13, 2010
- Integrate Hepatitis C testing with HIV: NGOs - Oct 21, 2011
- Painkiller used in hospitals, ambulances linked to hepatitis - Apr 18, 2011
- Clinical trial offers hope for Hepatitis C patients - Mar 15, 2011
- Beware! You may be more vulnerable to hepatitis than you think (July 28 is World Hepatitis Day) - Jul 27, 2012
- Hepatitis could kill 5 mn in Southeast Asia: WHO - Jul 24, 2012
- Turmeric could prevent liver damage - Oct 30, 2010
- Coffee may be good for chronic hepatitis C patients - Oct 21, 2009
- New therapy could help beat Hepatitis C virus - Jan 17, 2012
- New find may offer protection against hepatitis C treatment-related anemia - Jan 26, 2011
- Without mass vaccination, India vulnerable to hepatitis - Apr 26, 2011
- 'Pregnant women more vulnerable to Hepatitis E-induced liver failure' (July 28 is World Hepatitis Day) - Jul 26, 2012
Tags: bisceglie, boffins, chronic hepatitis c, control groups, doesnt work, health decline, hepatitis c, hepatology, initial course, internal medicine, liver cancer, liver center, liver disease, liver failure, maintenance therapy, medicine chief, patients with chronic hepatitis, peginterferon, saint louis university, viral therapy